HONG KONG – A Chinese biopharma has received approval from South Korean regulators to conduct local clinical trials on its biosimilar drug. Genor Biopharma Co. Ltd., a subsidiary of Walvax Biotechnology Co. Ltd. since last October, received clinical trial approval from the Korean Ministry of Food and Drug Safety (MFDS) for GB232, a biosimilar version of Abbvie Inc.'s Humira.